

# IF YOU COULD PREVENT SHINGLES, WHY WOULDN'T YOU?



Patient  
portrayal.

Protecting patients starts with a strong recommendation from you.

## Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

## Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see additional Important Safety Information for SHINGRIX throughout and full [Prescribing Information](#), also available at [SHINGRIXHCP.com](#).



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

# THE RISK IS GREATER THAN YOU MAY THINK

- 99.5% of people  $\geq 50$  years old are infected with the varicella zoster virus<sup>1,2</sup>
- In 1 out of 3 people, the dormant virus reactivates in their lifetime and causes shingles<sup>1</sup>
- Shingles can lead to complications such as postherpetic neuralgia (PHN) and herpes zoster ophthalmicus (HZO)<sup>1,\*</sup>
  - PHN occurs in 10% to 18% of shingles cases, and HZO occurs in 10% to 25% of shingles cases<sup>1</sup>

\*SHINGRIX is not indicated for the prevention of PHN or other herpes zoster-related complications.<sup>3</sup>

## Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX

Please see additional Important Safety Information for SHINGRIX throughout and full [Prescribing Information](#), also available at [SHINGRIXHCP.com](http://SHINGRIXHCP.com).

## SHINGRIX DELIVERED

# >90%

### EFFICACY AGAINST SHINGLES

regardless of age in those 50 years and older<sup>3,†</sup>

<sup>†</sup>Data from the phase 3 ZOE-50 ( $\geq 50$  years old) trial (median follow-up period 3.1 years) and pooled data in individuals  $\geq 70$  years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.<sup>3,4</sup>



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

# STORAGE, RECONSTITUTION, AND ADMINISTRATION<sup>3</sup>

Please refer to the full Prescribing Information for SHINGRIX for full details.

- Prior to reconstitution, store both the antigen (powder) and adjuvant (liquid) components refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze; discard if frozen and protect from light
- After reconstitution, administer immediately or store refrigerated between 2°C and 8°C (36°F and 46°F) for up to 6 hours. Discard reconstituted vaccine if not used within 6 hours. Do not freeze; discard if frozen

## DO NOT FREEZE<sup>3</sup>

**Vial 1 of 2**  
AS01<sub>B</sub> Adjuvant  
Suspension Component  
(liquid)



**Vial 2 of 2**  
Lyophilized VZV gE  
Antigen Component  
(powder)




**1** Cleanse both vial stoppers. Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the adjuvant suspension component (liquid) by slightly tilting the vial. Vial 1 of 2.




**2** Slowly transfer entire contents of the syringe into the lyophilized gE antigen component vial (powder). Vial 2 of 2.



**3** Gently swirl the vial until powder is completely dissolved. **Do not shake vigorously.** The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid.



**4** After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine and administer intramuscularly (IM).



gE=glycoprotein E; VZV=varicella zoster virus.

## Important Safety Information (cont'd)

- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)

Please see additional Important Safety Information for SHINGRIX throughout and full [Prescribing Information](#), also available at [SHINGRIXHCP.com](#).



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

## WHAT YOU SAY MATTERS

Your strong recommendation can positively influence your patients' shingles vaccination decision.<sup>5</sup>

**To communicate the importance of vaccination with SHINGRIX, follow a simple 3-step plan:**

### 1. EDUCATE PATIENTS ON SHINGLES

Explain that shingles is a painful, blistering rash that can last 7-10 days and may lead to complications.<sup>1,6,\*</sup> Starting at 50 years old, shingles risk sharply increases.<sup>1</sup>

### 2. MAKE THE RISK OF SHINGLES RELATABLE

Personalize your recommendation by using pronouns such as “you” along with connecting to the patient’s age group. Share an experience of the impact shingles has had on your patients and the importance of vaccination.

### 3. ADMINISTER OR SCHEDULE TODAY

Review the benefits and risks of getting SHINGRIX and explain the importance of receiving both doses. Administer or schedule today at [ScheduleSHINGRIX.com](https://www.scheduleshingrix.com).

\*SHINGRIX is not indicated for the prevention of herpes zoster-related complications.<sup>3</sup>

## Important Safety Information (cont'd)

- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women

Please see additional Important Safety Information for SHINGRIX throughout and full [Prescribing Information](#), also available at [SHINGRIXHCP.com](https://www.shingrixhcp.com).



See full Prescribing Information for data on coadministration of SHINGRIX with certain other adult vaccines.

Scan QR code or visit [cdc.gov/shingles/hcp/vaccine-considerations/index.html](https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html) to review CDC guidance

CDC=Centers for Disease Control and Prevention.



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

# SHINGRIX IS \$0 FOR MOST PATIENTS ≥50 YEARS OLD<sup>7,8,\*</sup>

## For your patients with commercial insurance plans<sup>†</sup>:

- [98%] of commercial patients pay \$0 for SHINGRIX<sup>7</sup>
- Average copays are just [\$4] or less<sup>7</sup>

## For your Medicare Part D patients:

- Medicare Part D patients can now get SHINGRIX for \$0 through their pharmacy<sup>8</sup>

Scan QR code or visit [www.shingrixhcp.com/in-your-practice/coverage-and-coding/](http://www.shingrixhcp.com/in-your-practice/coverage-and-coding/) to use the Coverage Tool to get real-time information about formulary coverage for SHINGRIX in your area



\*Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.

<sup>†</sup>SOURCE: Based on IQVIA data of paid [2023] SHINGRIX claims.


## Important Safety Information (cont'd)

- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information for SHINGRIX throughout and full [Prescribing Information](#), also available at [SHINGRIXHCP.com](http://SHINGRIXHCP.com).

## SHINGRIX IS GIVEN AS A 2-DOSE SERIES

- Administer the second dose 2 to 6 months after the first dose<sup>3</sup>
- **It is important patients receive both doses.** The efficacy results of SHINGRIX were demonstrated in clinical trials when administered as a 2-dose series<sup>3</sup>



Help ensure your patients complete the 2-DOSE SERIES OF SHINGRIX by scheduling their next appointment



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

# HOW SHINGRIX IS SUPPLIED<sup>3</sup>



SHINGRIX is supplied as an outer carton of 10 doses (NDC 58160-823-11) containing:

- Adjuvant Suspension Component (10 vials)  
NDC 58160-829-03
- Lyophilized gE Antigen Component (10 vials)  
NDC 58160-828-03



If you have any questions regarding SHINGRIX, call 1-800-772-9292 or visit [SHINGRIXHCP.com](https://www.shingrixhcp.com)



Encourage patients to schedule their pharmacy vaccine appointment at [ScheduleSHINGRIX.com](https://www.scheduleshingrix.com)

Please see additional Important Safety Information for SHINGRIX throughout and full [Prescribing Information](https://www.shingrixhcp.com), also available at [SHINGRIXHCP.com](https://www.shingrixhcp.com).

**References:** **1.** Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2008;57(RR-5):1-30. **2.** Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol.* 2003;70(suppl 1):S111-S118. **3.** Prescribing Information for SHINGRIX. **4.** Data on file. Study 113077 (NCT01165229). GSK Study Register. Study entry at: <https://www.gsk-studyregister.com/en/trial-details/?id=113077> **5.** Adult immunization standards. Centers for Disease Control and Prevention. August 9, 2024. Accessed August 28, 2024. <https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.html> **6.** Shingles symptoms and complications. Centers for Disease Control and Prevention. April 19, 2024. Accessed May 21, 2024. <https://www.cdc.gov/shingles/signs-symptoms/index.html> **7.** Data on file, GSK. **8.** Kirchhoff SM. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022;1-3. Accessed March 1, 2024. <https://crsreports.congress.gov/product/pdf/IF/IF12203>



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)



Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.  
PMUS-SGXLBN240014 October 2024  
Produced in USA.